$31.55
1.50% yesterday
Nasdaq, Sep 03, 10:00 pm CET
ISIN
US90400D1081
Symbol
RARE

Ultragenyx Pharmaceutical, Inc. Stock price

$31.55
+3.09 10.86% 1M
-9.71 23.53% 6M
-10.52 25.01% YTD
-24.16 43.37% 1Y
-16.20 33.93% 3Y
-46.54 59.60% 5Y
-84.70 72.86% 10Y
-10.70 25.33% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
-0.48 1.50%
ISIN
US90400D1081
Symbol
RARE
Industry

Key metrics

Basic
Market capitalization
$3.0b
Enterprise Value
$2.6b
Net debt
positive
Cash
$487.6m
Shares outstanding
96.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
5.0 | 4.5
EV/Sales
4.2 | 3.8
EV/FCF
negative
P/B
20.1
Financial Health
Equity Ratio
17.0%
Return on Equity
-223.0%
ROCE
-49.9%
ROIC
-70.7%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$610.2m | $670.7m
EBITDA
$-469.7m | $-428.5m
EBIT
$-505.1m | $-472.7m
Net Income
$-532.9m | $-495.3m
Free Cash Flow
$-442.3m
Growth (TTM | estimate)
Revenue
26.8% | 19.7%
EBITDA
8.9% | 19.2%
EBIT
8.0% | 11.8%
Net Income
8.9% | 13.0%
Free Cash Flow
10.2%
Margin (TTM | estimate)
Gross
85.3%
EBITDA
-77.0% | -63.9%
EBIT
-82.8%
Net
-87.3% | -73.9%
Free Cash Flow
-72.5%
More
EPS
$-5.4
FCF per Share
$-4.6
Short interest
9.0%
Employees
1k
Rev per Employee
$430.0k
Show more

Is Ultragenyx Pharmaceutical, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Ultragenyx Pharmaceutical, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Ultragenyx Pharmaceutical, Inc. forecast:

25x Buy
93%
2x Hold
7%

Analyst Opinions

27 Analysts have issued a Ultragenyx Pharmaceutical, Inc. forecast:

Buy
93%
Hold
7%

Financial data from Ultragenyx Pharmaceutical, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
610 610
27% 27%
100%
- Direct Costs 90 90
45% 45%
15%
521 521
24% 24%
85%
- Selling and Administrative Expenses 337 337
9% 9%
55%
- Research and Development Expense 688 688
5% 5%
113%
-470 -470
9% 9%
-77%
- Depreciation and Amortization 35 35
7% 7%
6%
EBIT (Operating Income) EBIT -505 -505
8% 8%
-83%
Net Profit -533 -533
9% 9%
-87%

In millions USD.

Don't miss a Thing! We will send you all news about Ultragenyx Pharmaceutical, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ultragenyx Pharmaceutical, Inc. Stock News

Neutral
GlobeNewsWire
5 days ago
NOVATO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced participation in three upcoming investor conferences.
Neutral
GlobeNewsWire
13 days ago
NOVATO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 113,572 restricted stock units of the company's common stock to 33 newly hired non-executive officers of the company. The awards were approved...
Neutral
GlobeNewsWire
17 days ago
Company expects to complete BLA submission in the fourth quarter of 2025 Company expects to complete BLA submission in the fourth quarter of 2025
More Ultragenyx Pharmaceutical, Inc. News

Company Profile

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.

Head office United States
CEO Emil Kakkis
Employees 1,294
Founded 2010
Website www.ultragenyx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today